Kreftlex - the free cancer resource
Kreftlex editorial board at the ICGI is thrilled with the news that the NGO @Legatene now ensures continued operation and development by taking financial responsibility for www.kreftlex.no.
Read more about the Kreftlex project here
More accurate diagnostics for prostate cancer patients
Anyone who has been waiting on the results of a cancer test knows how horrible that time can be." Professor Håvard E. Danielsen has authored a blog-post on what artificial intelligence (AI) can do for prostate cancer patients (In Norwegian).
Click here to go to the Oslo University Hospital blog: "The expert Hospital"
What can digital image analysis do for cancer patients?
The atmosphere was informal when Professor Fritz Albregtsen of UiO and Institute for Cancer Genetics and Informatics - ICGI was interviewed by Teknisk Ukeblad`s journalist profile Odd Richard Valmot and chief editor Jan M Moberg about the possibility of using technological methods for prognosticating prostate cancer and other cancers.
Professor Albrigtsen is connected to our DoMore! project.
To read the article in Teknisk Ukeblad, and listen to the podcast, please click here.
A Lancet Oncology Podcast
The Lancet Oncology is a monthly journal, renowned for the publication of high-quality peer reviewed research, reviews and analysis in cancer from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue. In February 2018, Håvard Emil Danielsen joined The Lancet Oncology to discuss his latest paper on machine learning algorithms to analyse chromatin organisation as a prognostic marker for cancer.
Listen to Professor Håvard E. Danielsen from ICGI explain how machine learning and deep learning can supplement today's diagnostic methods for cancer. The conversation is based on the recently published article Chromatin Organization and Cancer Prognosis: a pan-cancer study.
A link to the podcast may be found here.
Ten years of CCB - a story of success
This final report summarizes ten years of excellent research at CCB – Centre for Cancer Biomedicine - a Norwegian Center of Excellence (CoE) at the Faculty of Medicine 2007–2017. Three of the highlighted achievements are:
- Identified characteristics of cancers that enable us to diagnose cancer at an early stage and tailor therapy to the individual patient.
- Uncovered fundamental molecular mechanisms of cancer suppression and development that provide new opportunities for diagnosis and therapy.
- With the world-leading interdisciplinary journals Nature and Science as a benchmark, CCB is among the most successful Norwegian CoEs with 13 papers in these journals. CCB scientists are senior authors of 8 of them.
Click here to read the full report from the Centre for Cancer Biomedicine
The same test, regardless of cancer type
Researchers at the Institute for Cancer Genetics and Informatics at Oslo University Hospital (OUS), have developed a method that can assess the seriousness of a patient's cancer and what treatment is required. A test can help understand the development of almost all types of cancer, and the results are now published in The Lancet Oncology: Chromatin organization and cancer prognosis: a pan-cancer study.
Today, there is no common test to diagnose and predict cancer. Instead, a variety of tests and methods are used for different types of cancer. Very few of them can provide a certain answer as to how cancer will develop. The consequence is that it is difficult to distinguish patients who need more treatment after surgery from those who do not need ANY. A significant number of patients today receive too much treatment, which may cause unnecessary side effects, damage and at worst, death.
The fresh research results are based on more than 20 years of collaboration between the Department of Cancer Genetics and Informatics at OUS and the Department of Informatics at The University of Oslo.
Initially, the method will be particularly useful for finding patients with Stage II intestinal cancer who will need more treatment after surgery, usually chemotherapy. Experiments show that the method can also be used for ovarian cancer, uterine cancer and prostate cancer.
Click here to read more about the Nucleotyping method.
As a supplement to the article on the Lancet Oncology website, a 3d animation was made by our unit for Dissertation and Visualization:
Annual Report 2017 from ICGI
2017 marked the end of ten successful years of CCB and was also the first full year of the DoMore! Project, one of the prestigious Lighthouse projects awarded 60 million NOK by the Norwegian Research Council. With in silico pathology and an international consortium led by ICGI, the project aims to solve some of the large-scale societal challenges that cancer poses.
A summary of the Institute activities is reported in our annual report for 2017. Click here to download the pdf.
Animation on Deep Learning & Convolutional Networks
What can big data and deep learning do for cancer treatment? Watch our new video created by our researchers at www.domore.no and the Unit for Dissemination and Visualisation!
Click here to read our article on Deep Learning.
An article on Håkon Wæhres long time registration of patient data available in "Science Nordic"
After a life in service for prostate patients and fifty years of data collection, urologist Håkon Wæhre contributes to our research project DoMore! and the development of machines that will more accurately be able to assess how dangerous the patient's cancer is.
We truly appreciate Dr Wæhre's dedication to our research group at the ICGI. His presence and encouragements will be missed now he has chosen to retire.
Please click here to read the article in Science Nordic about how Dr. Wæhre's research efforts contribute to our DoMore! project.
Danielsen appointed Visiting Professor at University of Oxford
The University of Oxford's Medical Sciences Board has conferred on Håvard Danielsen the title of Visiting Professor of Cancer Informatics in recognition of his important contributions towards the successful and fruitful collaboration with their University.
The University of Oxford is a partner in the DoMore! project,, and Institute Director, Håvard E. Danielsen, also serves as chair of the panel of expertise in the Colorectal Cancer Research Collaboration Network ( crcnetwork.net),. The network includes representatives from some of the highest-ranked universities in Europe, the University of Oxford being among them.